Key points are not available for this paper at this time.
We developed and implemented in multicenter setting the standardized approach for flow cytometric minimal residual disease (MRD) monitoring in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Participation of multicenter group reference laboratories in several ring trial studies demonstrated high concordance rate between participants. Successful integration of one additional laboratory in the multicenter group has shown good level of our approach reproducibility. These results will allow implementing MRD detection in stratification system of pediatric ALL treatment protocols of Russia-Belarus multicenter group.
Попов et al. (Sat,) studied this question.